← All trials
NCT05650749
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 30, 2023
- Primary completion
- Jan 30, 2025
- Completion date
- Jan 30, 2026
- First posted
- Dec 14, 2022
- Last posted
- Dec 23, 2022
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of PennsylvaniaLead sponsor
- University of PennsylvaniaCollaborator
- University of PennsylvaniaCollaborator
- University of PennsylvaniaOverall official - principal investigator
- University of PennsylvaniaSponsor investigator
- Tmunity TherapeuticsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.